- DKK51.19bn
- DKK58.42bn
- DKK24.63bn
DB downgrades Lundbeck to 'sell' on Rexulti patent cliff risk
Europe Research Roundup: ASM International, Michelin, Nokian Renkaat
Europe Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options
Avadel shares jump as Alkermes raises buyout bid
Alkermes raises offer for Avadel after Lundbeck bid (updated)
Brief: Avadel Board Of Directors Declares Lundbeck Proposal A “Company Superior Proposal”
Nasdaq biotech index hits record high, set to gain nearly 5% this week
Advel jumps after Lundbeck's unsolicited bid
Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel (updated)
Europe Research Roundup: Beijer Ref, DKSH Holding, Yara
Brief: Otsuka And Lundbeck Receive Complete Response Letter From U.S. FDA For SNDA Of Rexulti® (Brexpiprazole) In Combination With Sertraline For The Treatment Of Adults With PTSD
Europe Research Roundup: BMW, Fugro, Mercedes-Benz
FDA staff raises efficacy concerns for Otsuka's PTSD combination drug (updated)
FDA staff raises efficacy concerns for Otsuka's PTSD combination drug
European pharmaceuticals fall on looming U.S. tariffs